KROS
Keros Therapeutics, Inc.
$11.28
-0.62%
2026-10-23
About Keros Therapeutics, Inc.
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Key Fundamentals
P/E Ratio
5.00
Forward P/E
-1.76
EPS (TTM)
$-3.20
ROE
-17.2%
Revenue Growth (YoY)
-99.8%
Profit Margin
0.0%
Debt/Equity
5.99
Price/Book
0.88
Beta
1.02
Market Cap
$230.4M
Avg Volume (10D)
229K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$12.26
60D Low
$9.69
Avg Volume
191K
Latest Close
$11.28
Get breakout alerts for KROS
Sign up for Breakout Scanner to receive daily notifications when KROS triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
Keros Therapeutics, Inc. (KROS) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors KROS daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. KROS operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.